glp 1 agonist buy GLP-1 costs rise, but there are ways to save on weight-loss drugs GLP-1 Receptor Agonists: Market Momentum
Description
Diabetes and obesity are significant risk factors for morning hypertension: from Ibaraki Hypertension Assessment Trial (I-HAT)
This first wave of GLP-1s were commercially successful (Victoza saw peak sales of ~$3.8B in 2018), but results were modest relative to todays market
GLP-1 agonists primarily aid in weight loss and cardiovascular protection, while SGLT2 inhibitors provide strong kidney and heart failure benefits
Diabetes Care 36 Suppl 2: S245-252, 2013
In the matched cohort, the reduction was 30.5%
